AR035679A1 - PHARMACEUTICALLY ACCEPTABLE SALES OF ACID 3S, 4AR, 8AR-6 - (((2S) -2- (CARBOXIL) -4.4, -DIFLUORPIRROLIDINIL) METHYL) -1,2,3,4,4A, 5,6,7 , 8,8A-DECAHYDROISOQUINOLIN-3-CARBOXILICO, DRUGS OF SUCH COMPOUNDS; METHOD TO TREAT NEUROLOGICAL OR NEURODEGENERATIVE DISORDERS USING SALES SALES; USE OF THE - Google Patents
PHARMACEUTICALLY ACCEPTABLE SALES OF ACID 3S, 4AR, 8AR-6 - (((2S) -2- (CARBOXIL) -4.4, -DIFLUORPIRROLIDINIL) METHYL) -1,2,3,4,4A, 5,6,7 , 8,8A-DECAHYDROISOQUINOLIN-3-CARBOXILICO, DRUGS OF SUCH COMPOUNDS; METHOD TO TREAT NEUROLOGICAL OR NEURODEGENERATIVE DISORDERS USING SALES SALES; USE OF THEInfo
- Publication number
- AR035679A1 AR035679A1 ARP020100030A ARP020100030A AR035679A1 AR 035679 A1 AR035679 A1 AR 035679A1 AR P020100030 A ARP020100030 A AR P020100030A AR P020100030 A ARP020100030 A AR P020100030A AR 035679 A1 AR035679 A1 AR 035679A1
- Authority
- AR
- Argentina
- Prior art keywords
- sales
- pharmaceutically acceptable
- compounds
- acid
- difluorpirrolidinil
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
Se describen y reivindican sales farmacéuticamente aceptables de los compuestos de fórmula (1) ó profármacos del mismo, seleccionadas dichas sales farmacéuticamente aceptables, del grupo constituido por la sal del ácido D-(-)-mandélico o la sal del ácido 1,5-naftalendisulfónico. Inclusive prodrogas de los compuestos mencionados y los objetos restantes mencionados en el título. Dichas sales son de aplicación como antagonistas selectivos de los receptores pertenecientes al subtipo iGluR5, de utilidad en el tratamiento de enfermedades neurodegenerativas; v. gr.: trastornos neurológicos sin efectos secundarios.Pharmaceutically acceptable salts of the compounds of formula (1) or prodrugs thereof, said pharmaceutically acceptable salts, are selected and claimed from the group consisting of the salt of D - (-) - mandelic acid or the salt of 1,5- Naphthalenedisulfonic acid Including prodrugs of the mentioned compounds and the remaining objects mentioned in the title. Said salts are applicable as selective antagonists of the receptors belonging to the subtype iGluR5, useful in the treatment of neurodegenerative diseases; v. gr .: neurological disorders without side effects.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26001401P | 2001-01-05 | 2001-01-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR035679A1 true AR035679A1 (en) | 2004-06-23 |
Family
ID=22987455
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020100030A AR035679A1 (en) | 2001-01-05 | 2002-01-04 | PHARMACEUTICALLY ACCEPTABLE SALES OF ACID 3S, 4AR, 8AR-6 - (((2S) -2- (CARBOXIL) -4.4, -DIFLUORPIRROLIDINIL) METHYL) -1,2,3,4,4A, 5,6,7 , 8,8A-DECAHYDROISOQUINOLIN-3-CARBOXILICO, DRUGS OF SUCH COMPOUNDS; METHOD TO TREAT NEUROLOGICAL OR NEURODEGENERATIVE DISORDERS USING SALES SALES; USE OF THE |
Country Status (23)
| Country | Link |
|---|---|
| EP (1) | EP1351955A1 (en) |
| JP (1) | JP2004520335A (en) |
| KR (1) | KR20030066797A (en) |
| CN (1) | CN1484642A (en) |
| AR (1) | AR035679A1 (en) |
| BR (1) | BR0116672A (en) |
| CA (1) | CA2431545A1 (en) |
| CZ (1) | CZ20031856A3 (en) |
| DZ (1) | DZ3460A1 (en) |
| EA (1) | EA200300770A1 (en) |
| EC (1) | ECSP034682A (en) |
| HR (1) | HRP20030544A2 (en) |
| HU (1) | HUP0302528A2 (en) |
| IL (1) | IL156138A0 (en) |
| MX (1) | MXPA03005981A (en) |
| NO (1) | NO20032973D0 (en) |
| NZ (1) | NZ525821A (en) |
| PE (1) | PE20020792A1 (en) |
| PL (1) | PL361934A1 (en) |
| SK (1) | SK8242003A3 (en) |
| TW (1) | TW591023B (en) |
| WO (1) | WO2002053561A1 (en) |
| ZA (1) | ZA200304311B (en) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5284957A (en) * | 1992-09-03 | 1994-02-08 | Eli Lilly And Company | Excitatory amino acid receptor antagonists |
| PL342295A1 (en) * | 1998-02-06 | 2001-06-04 | Smithkline Beecham Plc | Paroxetin salts |
| GB9908175D0 (en) * | 1999-04-09 | 1999-06-02 | Lilly Co Eli | Method of treating neurological disorders |
| NZ515616A (en) * | 1999-07-06 | 2004-05-28 | Lilly Co Eli | Selective iGluR5 receptor antagonists for the treatment of migraine |
-
2001
- 2001-12-20 SK SK824-2003A patent/SK8242003A3/en unknown
- 2001-12-20 JP JP2002554680A patent/JP2004520335A/en active Pending
- 2001-12-20 IL IL15613801A patent/IL156138A0/en unknown
- 2001-12-20 MX MXPA03005981A patent/MXPA03005981A/en unknown
- 2001-12-20 WO PCT/US2001/044715 patent/WO2002053561A1/en not_active Application Discontinuation
- 2001-12-20 NZ NZ525821A patent/NZ525821A/en unknown
- 2001-12-20 CN CNA018217508A patent/CN1484642A/en active Pending
- 2001-12-20 BR BR0116672-7A patent/BR0116672A/en not_active IP Right Cessation
- 2001-12-20 CZ CZ20031856A patent/CZ20031856A3/en unknown
- 2001-12-20 EA EA200300770A patent/EA200300770A1/en unknown
- 2001-12-20 PL PL01361934A patent/PL361934A1/en not_active Application Discontinuation
- 2001-12-20 HU HU0302528A patent/HUP0302528A2/en unknown
- 2001-12-20 DZ DZ013460A patent/DZ3460A1/en active
- 2001-12-20 CA CA002431545A patent/CA2431545A1/en not_active Abandoned
- 2001-12-20 KR KR10-2003-7008977A patent/KR20030066797A/en not_active Application Discontinuation
- 2001-12-20 EP EP01995980A patent/EP1351955A1/en not_active Withdrawn
-
2002
- 2002-01-04 AR ARP020100030A patent/AR035679A1/en not_active Application Discontinuation
- 2002-01-04 PE PE2002000003A patent/PE20020792A1/en not_active Application Discontinuation
- 2002-01-04 TW TW091100071A patent/TW591023B/en not_active IP Right Cessation
-
2003
- 2003-06-02 ZA ZA200304311A patent/ZA200304311B/en unknown
- 2003-06-27 NO NO20032973A patent/NO20032973D0/en not_active Application Discontinuation
- 2003-07-03 HR HR20030544A patent/HRP20030544A2/en not_active Application Discontinuation
- 2003-07-03 EC EC2003004682A patent/ECSP034682A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NZ525821A (en) | 2004-07-30 |
| NO20032973L (en) | 2003-06-27 |
| HUP0302528A2 (en) | 2003-11-28 |
| EA200300770A1 (en) | 2003-10-30 |
| HRP20030544A2 (en) | 2004-08-31 |
| NO20032973D0 (en) | 2003-06-27 |
| TW591023B (en) | 2004-06-11 |
| BR0116672A (en) | 2003-09-23 |
| EP1351955A1 (en) | 2003-10-15 |
| ECSP034682A (en) | 2003-08-29 |
| PE20020792A1 (en) | 2002-09-06 |
| CZ20031856A3 (en) | 2003-09-17 |
| PL361934A1 (en) | 2004-10-18 |
| DZ3460A1 (en) | 2002-07-11 |
| CN1484642A (en) | 2004-03-24 |
| KR20030066797A (en) | 2003-08-09 |
| SK8242003A3 (en) | 2004-01-08 |
| IL156138A0 (en) | 2003-12-23 |
| MXPA03005981A (en) | 2003-09-10 |
| JP2004520335A (en) | 2004-07-08 |
| ZA200304311B (en) | 2004-09-02 |
| WO2002053561A1 (en) | 2002-07-11 |
| CA2431545A1 (en) | 2002-07-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP034712A (en) | CICLOBUTENO-1.2-DIONAS 3,4-DI-SUBSTITUTED AS ANTAGONISTS OF THE CXC CHEMIOCINE RECEIVER | |
| ECSP034640A (en) | DERIVATIVES OF PHENYLETENYL OR PHENYLETINYL AS ANTAGONISTS OF THE GLUTAMATE RECEIVER | |
| ECSP056115A (en) | ANTAGONISTS OF A2A-2-ALQUINIL- AND 2-ALQUENIL-PIRAZOLO- [4,3-e] -1,2,4-TRIAZOLO- [1,5-c] -PIRIMIDINE ADENOSINE RECEPTOR | |
| ECSP034744A (en) | N-REPLACED N-REPLACED NMDA / NR2B ANTAGONISTS | |
| CR8349A (en) | DIHYDROBENZOFURANYL ALCANAMINE DERIVATIVES AND METHODS FOR USE | |
| AR047992A1 (en) | DIAMINOPIRIMIDINS AS ANTAGONISTS OF P2X3 AND P2X2 / 3 | |
| PA8591701A1 (en) | PIRROLOPIRIMIDINE DERIVATIVES | |
| CY1111977T1 (en) | PEPERIDIN-4-YL-PYRIDAZIN-3-YLAMINE DERIVATIVES AS HIGHLY DISTRIBUTED DOPAMIN COMPONENTS 2 | |
| UY29710A1 (en) | TRICYCLIC BENZIMIDAZOLS AND THEIR USE AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | |
| PE20010205A1 (en) | 3-SUBSTITUTED DERIVATIVES OF 2-CARBOXYCLOPROPYL GLYCINE AS GLUTAMATE AGONISTS | |
| EA200600190A1 (en) | DERIVATIVES OF PYRIMIDIN-2,4-DIONA AS ANTAGONISTS OF THE GONADOTROPYN-SURVIVER HORMONE RECEPTOR ANTAGONISTS | |
| GT199800021A (en) | USE OF ANTAGONISTS OF CENTRAL CANABINOID RECEPTORS FOR THE PREPARATION OF MEDICINES. | |
| EA201170473A1 (en) | MORPHINAN COMPOUNDS | |
| BR0104834A (en) | Glucocorticoid receptor modulators | |
| AR028824A1 (en) | NPY-5 ANTAGONIST COMPOUNDS AND ITS USE IN THE MANUFACTURE OF MEDICINES. | |
| AR040278A1 (en) | GLUCOCORTICOID RECEIVER LINKS FOR THE TREATMENT OF METABOLIC DISORDERS | |
| ECSP056192A (en) | 3-FLUORO-PIPERIDINS AS ANTAGONISTS OF NMDA / NR2B | |
| CY1106645T1 (en) | 1,2,4 TRIAMINOBENZENE DERIVATIVES USEFUL FOR THE THERAPEUTIC TREATMENT OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM | |
| DE60120077D1 (en) | Modulators of the glucocorticoid receptor | |
| CL2004000769A1 (en) | ACID-DERIVED COMPOUNDS [2- (8,9-DIOXO-2,6-DIAZABICICLO [5,2, O] NON-1- (7) -EN-2-IL) RENT] PHOSPHONIC, N-METHYL RECEPTOR ANTAGONISTS -D-ASPARTATO (NMDA); PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION; AND ITS USE TO TREAT DISORDERS GOES | |
| AR066701A1 (en) | 3- (IMIDAZOLIL) - PIRAZOLO {3,4-B] PIRIDINES, PHARMACEUTICAL COMPOSITION, PROCESS AND USE IN THERAPY | |
| ES2156287T3 (en) | DERIVATIVES OF DIFENILMETILEN PIPERIDINA. | |
| AR029373A1 (en) | METHOD FOR THE TREATMENT OF MIGRANES, USING SELECTIVE ANTAGONIST COMPOUNDS OF THE IGLUR5 RECEPTORS, USE OF SUCH SELECTIVE ANTAGONIST COMPOUNDS IN THE MANUFACTURE OF MEDICINES FOR THE TREATMENT OF MIGRANES AND SAVINGS COMPOSED | |
| BRPI0417520A (en) | Substituted 1h-pyrrolo [3,2-b, 3,2-c, and 2,3-c] pyridine-2-carboxamides and analogues reported as inhibitors of i-epsilon casein kinase | |
| UY26919A1 (en) | DERIVATIVES OF QUINAZOLINE AS ALFA ADRENERGIC ANTAGONISTS - 1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal | ||
| FA | Abandonment or withdrawal |